Holdings derived from the most recent reported transactions. Not adjusted for stock splits or share-class conversions.
| Issuer | Shares | Source | Last tx | Detail |
|---|---|---|---|---|
| Flywire Corp | 6,829,032 | reported | 28 May 2021 | tx 10+7,268,490−7,268,490 |
| Neumora Therapeutics, Inc. | 5,387,375 | reported | 19 Sept 2023 | tx 8+3,712,624−3,712,624 |
| Sana Biotechnology, Inc. | 4,707,423 | reported | 08 Jan 2025 | tx 4−290,912 |
| Orchard Therapeutics plc | 4,099,540 | reported | 19 Feb 2021 | tx 10+828,457−2,884,935 |
| PRECISION BIOSCIENCES INC | 3,688,248 | reported | 01 Apr 2019 | tx 5+3,738,248−7,873,253 |
| XOOM Corp | 2,619,036 | reported | 28 Aug 2013 | tx 13+3,184,272−13,302,331 |
| Cogent Biosciences, Inc. | 1,937,235 | reported | 03 Apr 2018 | tx 13+2,412,590−3,640,413 |
| Aclaris Therapeutics, Inc. | 1,931,727 | reported | 19 Dec 2016 | tx 13+15,771,725−1,872,552 |
| Surface Oncology, Inc. | 1,888,986 | reported | 23 Apr 2018 | tx 2+1,888,986−4,155,773 |
| Ultragenyx Pharmaceutical Inc. | 1,457,994 | reported | 01 Aug 2014 | tx 6+3,260,240−11,472,943 |
| Date | Type | Issuer | Qty | Price | Signals |
|---|---|---|---|---|---|
| 27 May 2026 | OTHER | Aeon Credit Service (Asia) Co. Ltd. | 1,398,000 | 8.52 HKD | |
| 27 May 2026 | OTHER | Hesai Group - W | 168,320 | 167.50 HKD | |
| 27 May 2026 | OTHER | Zai Lab Ltd. | 880,000 | — | |
| 26 May 2026 | OTHER | Hesai Group - W | 260,625 | — | |
| 26 May 2026 | PURCHASE | WuXi AppTec Co., Ltd. - H Shares | 74,000 | — | first after silence |
| 26 May 2026 | OTHER | Zai Lab Ltd. | 969,000 | — | |
| 01 May 2026 | CONVERSION | Avalyn Pharma Inc. | 727,585 | — | |
| 01 May 2026 | CONVERSION | Avalyn Pharma Inc. | 80,291 | — | |
| 01 May 2026 | CONVERSION | Avalyn Pharma Inc. | 872,868 | — | |
| 01 May 2026 | CONVERSION | Avalyn Pharma Inc. | 225,843 | — | |
| 01 May 2026 | CONVERSION | Avalyn Pharma Inc. | 377,948 | — | |
| 01 May 2026 | CONVERSION | Avalyn Pharma Inc. | 727,585 | — | deriv |
| 01 May 2026 | CONVERSION | Avalyn Pharma Inc. | 80,291 | — | deriv |
| 01 May 2026 | CONVERSION | Avalyn Pharma Inc. | 872,868 | — | deriv |
| 01 May 2026 | CONVERSION | Avalyn Pharma Inc. | 225,843 | — | deriv |
| 01 May 2026 | CONVERSION | Avalyn Pharma Inc. | 377,948 | — | deriv |
| 15 Jan 2026 | SALE | Structure Therapeutics Inc. | 6,498 | 84.22 USD | deriv |
| 15 Jan 2026 | SALE | Structure Therapeutics Inc. | 230 | 85.04 USD | deriv |
| 15 Jan 2026 | SALE | Structure Therapeutics Inc. | 3,880 | 83.35 USD | deriv |
| 15 Jan 2026 | SALE | Structure Therapeutics Inc. | 5,477 | 82.10 USD | deriv |
| 15 Jan 2026 | SALE | Structure Therapeutics Inc. | 20 | 85.04 USD | deriv |
| 15 Jan 2026 | SALE | Structure Therapeutics Inc. | 330 | 83.35 USD | deriv |
| 15 Jan 2026 | SALE | Structure Therapeutics Inc. | 465 | 82.10 USD | deriv |
| 15 Jan 2026 | SALE | Structure Therapeutics Inc. | 552 | 84.22 USD | deriv |
| 08 Dec 2025 | SALE | Structure Therapeutics Inc. | 475 | 94.61 USD | deriv |
4 purchases reported after at least 12 months of silence — most recent on 26 May 2026.